Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy

Cancer immunology research

Volumn 1, Issue 4, 2013, Pages 229-234

  Ng Tang, Derek ^a   Shen, Yu ^a   Sun, Jingjing ^a   Wen, Sijin ^a   Wolchok, Jedd D ^a   Yuan, Jianda ^a   Allison, James P ^a   Sharma, Padmanee ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CTLA4 PROTEIN, HUMAN; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DNA VACCINE; ICOS PROTEIN, HUMAN; INDUCIBLE T CELL COSTIMULATOR; IPILIMUMAB; MONOCLONAL ANTIBODY;

CD4+ T LYMPHOCYTE; FLOW CYTOMETRY; HUMAN; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MELANOMA; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY AND SPECIFICITY;

ANTIBODIES, MONOCLONAL; BIOMARKERS; CD4-POSITIVE T-LYMPHOCYTES; CTLA-4 ANTIGEN; CYTOKINES; FLOW CYTOMETRY; HEALTHY VOLUNTEERS; HUMANS; INDUCIBLE T-CELL CO-STIMULATOR PROTEIN; LYMPHOCYTE ACTIVATION; MELANOMA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SENSITIVITY AND SPECIFICITY; VACCINES, DNA;

EID: 85003055100     PISSN: None     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-13-0020     Document Type: Article

References (0)